title: Lessons from breast cancer trials of HER2-kinase inhibitors.
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: Ian_Krop@dfci.harvard.edu.
authors.forename: Ian E
authors.initials: IE
authors.lastname: Krop
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*; D000068878:Trastuzumab
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab